McAdam LLC Has $1.63 Million Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

McAdam LLC boosted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 132.6% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 22,258 shares of the biopharmaceutical company's stock after acquiring an additional 12,690 shares during the period. McAdam LLC's holdings in Gilead Sciences were worth $1,630,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of GILD. Altfest L J & Co. Inc. bought a new position in Gilead Sciences during the fourth quarter worth $210,000. Federated Hermes Inc. raised its position in shares of Gilead Sciences by 4.9% during the fourth quarter. Federated Hermes Inc. now owns 3,787,355 shares of the biopharmaceutical company's stock valued at $306,814,000 after buying an additional 175,925 shares during the last quarter. Wetzel Investment Advisors Inc. acquired a new position in shares of Gilead Sciences during the fourth quarter valued at about $74,000. Abundance Wealth Counselors bought a new stake in shares of Gilead Sciences in the third quarter valued at about $1,881,000. Finally, HTLF Bank acquired a new stake in Gilead Sciences during the fourth quarter worth about $253,000. 83.67% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

GILD has been the topic of a number of research reports. Cantor Fitzgerald lowered their price objective on Gilead Sciences from $80.00 to $78.00 and set a "neutral" rating on the stock in a research report on Wednesday, February 7th. Oppenheimer reissued an "outperform" rating and issued a $105.00 price target on shares of Gilead Sciences in a report on Friday, April 19th. Morgan Stanley dropped their price objective on shares of Gilead Sciences from $80.00 to $78.00 and set an "equal weight" rating for the company in a research note on Friday, April 26th. Wells Fargo & Company decreased their target price on shares of Gilead Sciences from $84.00 to $77.00 and set an "equal weight" rating on the stock in a research report on Monday, March 4th. Finally, UBS Group dropped their price target on shares of Gilead Sciences from $81.00 to $75.00 and set a "neutral" rating for the company in a research report on Wednesday, April 17th. Eleven equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Gilead Sciences presently has a consensus rating of "Hold" and an average price target of $83.69.

Insider Buying and Selling

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the company's stock in a transaction on Monday, April 1st. The shares were sold at an average price of $72.96, for a total transaction of $145,920.00. Following the completion of the sale, the insider now owns 96,304 shares in the company, valued at approximately $7,026,339.84. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.16% of the stock is currently owned by insiders.

Gilead Sciences Trading Down 0.3 %

NASDAQ:GILD traded down $0.18 during trading hours on Thursday, hitting $65.33. 5,570,630 shares of the stock were exchanged, compared to its average volume of 7,455,491. The company has a market capitalization of $81.34 billion, a P/E ratio of 181.47, a price-to-earnings-growth ratio of 1.31 and a beta of 0.22. The company has a quick ratio of 0.72, a current ratio of 0.98 and a debt-to-equity ratio of 1.08. The company's 50 day moving average is $70.72 and its two-hundred day moving average is $75.94. Gilead Sciences, Inc. has a twelve month low of $64.63 and a twelve month high of $87.86.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.49) by $0.17. The business had revenue of $6.69 billion for the quarter, compared to analyst estimates of $6.36 billion. Gilead Sciences had a return on equity of 24.34% and a net margin of 1.76%. The firm's revenue for the quarter was up 5.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.37 earnings per share. On average, sell-side analysts anticipate that Gilead Sciences, Inc. will post 3.74 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, June 27th. Stockholders of record on Friday, June 14th will be given a dividend of $0.77 per share. This represents a $3.08 annualized dividend and a dividend yield of 4.71%. The ex-dividend date is Friday, June 14th. Gilead Sciences's dividend payout ratio is 855.56%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.